ALX Oncology Holdings Inc. (ALXO) Income Statement
ALXO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsALXO revenue and net income
ALXO profit margins
ALXO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ALXO quarterly EPS vs estimates
ALX Oncology beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 6, 2026 (estimate $-0.14).
ALXO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.2M | $4.8M | $2.1M |
| Cost of revenue | — | $872,000 | $836,000 | $1.5M | $736,000 | $1.1M | $4.4M | $1.9M |
| Gross profit | — | −$872,000 | −$836,000 | −$1.5M | −$736,000 | $107,000 | $436,000 | $187,000 |
| Research & development | $77.0M | $116.4M | $141.8M | $98.4M | $60.2M | $29.0M | $16.3M | $11.3M |
| Sales, general & admin | $23.9M | $26.1M | $29.3M | $29.0M | $23.4M | $14.8M | $3.3M | $2.6M |
| Total operating expenses | $104.0M | $142.5M | $170.3M | $127.4M | $83.6M | $43.8M | $19.6M | $13.9M |
| Operating income | −$104.0M | −$142.5M | −$170.3M | −$127.4M | −$83.6M | −$43.7M | −$19.2M | −$13.7M |
| Interest income | $4.0M | $9.4M | $10.6M | $4.3M | $91,000 | $124,000 | $21,000 | — |
| Interest expense | $1.6M | $1.7M | $1.6M | $4.4M | $13,000 | $811,000 | $21,000 | $0 |
| Income before taxes | −$101.7M | −$134.8M | −$160.8M | −$123.4M | −$83.5M | −$45.5M | −$19.2M | −$13.7M |
| Income taxes | — | — | — | $64,000 | −$21,000 | $241,000 | $34,000 | $45,000 |
| Net income | −$101.7M | −$134.8M | −$160.8M | −$123.5M | −$83.5M | −$45.7M | −$19.2M | −$13.7M |
| EBITDA | −$99.4M | −$132.2M | −$158.4M | −$127.1M | −$83.4M | −$43.5M | −$18.8M | −$13.3M |
| EPS (diluted) | −$1.70 | −$2.35 | −$3.74 | −$3.03 | −$2.06 | −$3.60 | −$0.88 | −$4.58 |
| Gross margin | — | — | — | — | — | 9.1% | 9.1% | 9.0% |
| Operating margin | — | — | — | — | — | −3,694.0% | −400.0% | −662.0% |
| Net margin | — | — | — | — | — | −3,869.7% | −401.2% | −664.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $868,000 | $0 | $0 | $0 | $2.5M | $0 |
| Cost of revenue | — | $150,000 | — | — | $191,000 | $211,000 | $434,000 | $224,000 | $220,000 | $214,000 | $207,000 | $209,000 |
| Gross profit | — | −$150,000 | — | — | −$191,000 | −$211,000 | $434,000 | −$224,000 | −$220,000 | −$214,000 | −$207,000 | −$209,000 |
| Research & development | $13.1M | $13.6M | $17.6M | $17.4M | $18.0M | $23.9M | $23.5M | $26.5M | $34.7M | $31.7M | $41.8M | $45.8M |
| Sales, general & admin | $5.1M | $5.4M | $5.4M | $5.1M | $5.5M | $7.9M | $7.1M | $6.1M | $7.1M | $6.3M | $6.4M | $7.5M |
| Total operating expenses | $18.0M | $18.8M | $23.0M | $22.5M | $26.6M | $31.8M | $30.6M | $32.6M | $41.3M | $37.5M | $48.0M | $53.3M |
| Operating income | −$18.0M | −$19.0M | −$23.0M | −$22.5M | −$26.6M | −$31.8M | −$30.6M | −$32.6M | −$41.5M | −$37.8M | −$48.0M | −$53.3M |
| Interest income | $1.5M | $1.2M | $573,000 | $802,000 | $1.1M | $1.5M | $1.9M | $2.3M | $2.6M | $2.6M | $3.0M | $2.7M |
| Interest expense | $285,000 | $331,000 | $383,000 | $408,000 | $405,000 | $406,000 | $427,000 | $446,000 | $429,000 | $427,000 | $415,000 | $391,000 |
| Income before taxes | −$18.0M | −$17.9M | −$22.8M | −$22.1M | −$25.9M | −$30.8M | −$29.2M | −$30.7M | −$39.4M | −$35.6M | −$45.5M | −$51.0M |
| Income taxes | — | — | — | — | — | — | — | — | — | $170,724 | $1.1M | −$209,000 |
| Net income | −$18.0M | −$17.9M | −$22.8M | −$22.1M | −$25.9M | −$30.8M | −$29.2M | −$30.7M | −$39.4M | −$35.6M | −$45.5M | −$51.0M |
| EBITDA | −$17.6M | −$17.4M | −$22.3M | −$21.6M | −$25.4M | −$30.1M | −$28.5M | −$30.0M | −$38.8M | −$34.9M | −$44.9M | −$50.4M |
| EPS (diluted) | −$0.13 | −$0.17 | −$0.37 | −$0.41 | −$0.44 | −$0.48 | −$0.44 | −$0.58 | −$0.62 | −$0.71 | −$0.93 | −$1.24 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | −8.3% | — |
| Operating margin | — | — | — | — | — | — | −3,526.8% | — | — | — | −1,936.4% | — |
| Net margin | — | — | — | — | — | — | −3,359.8% | — | — | — | −1,833.5% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ALXO's financial statements (latest annual report filed March 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ALXO financial results
ALX Oncology reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $101.7 million. Diluted earnings per share came to −$1.70.
See the ALXO stock overview for the latest quote and news, or the ALXO chart for price history and technical indicators.
ALXO income statement FAQ
Does ALX Oncology have revenue?
ALX Oncology reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is ALX Oncology profitable?
No. ALX Oncology reported a net loss of $101.7 million in fiscal 2025.
How much does ALX Oncology spend on research and development?
ALX Oncology spent $77.0 million on research and development in fiscal 2025.
What are ALX Oncology's earnings per share?
ALX Oncology earned $-1.70 per diluted share in fiscal 2025, compared with $-2.35 a year earlier.
When will ALX Oncology report its next earnings?
ALX Oncology is expected to report results for the quarter ending September 30, 2026 on November 6, 2026 before the market opens.
When does ALX Oncology's fiscal year end?
ALX Oncology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 9, 2026.